转移性肾癌

低剂量白介素-2联合干扰素-α治疗转移性肾癌

Clinical observation of low-dose IL-2 and IFN - α in metastatic renal cell carcinoma

目的观察转移性肾癌不同组织学亚型间生物化疗的效应差异，探讨预测疗效的因素。

Objective To assess the biochemotherapeutic effects on different pathologic subtypes of metastatic renal cell carcinoma .

肾细胞癌（Renalcellcarcinoma，Rcc）是泌尿外科最常见的恶性肿瘤，近年来其发病率有逐渐增高的趋势，随影像学检查技术的进步，早期非转移性肾癌比例增高。

Renal cell carcinoma ( Rcc ) is the most common malignant tumor in Urology , its incidence in recent years there have been an increasing tendency , with the imaging examination and technological progress , the proportion of early non-metastatic renal cell carcinoma increased .

因此，努力探讨新的转移性肾癌的治疗方法显得十分必要。

Therefore , it is quite necessary to explore a new treatment for metastatic renal cell carcinoma .

结论转移性肾癌干扰素与长春花碱联合生物化疗疗效与组织学类型有关，透明细胞癌缓解率高。

Conclusions Interferon α 2b and vinblastine combination therapy showed high responses in patients with clear cell carcinoma whereas the response has been poor in other histologic types of metastatic renal cell carcinoma .

约50%的患者首次就诊时已属晚期，约40%的患者手术后转移或复发，转移性肾癌预后较差，平均存活时间小于1年，3年存活率低于5%。

40 percent of postoperative patients relapse or metastasize . The average survival time for metastatic RCC patients is below 1 year , and survival rate after 3 years is below 5 % .